AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2158257 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin 450 mg
Number of subjects: 406
Study 2158257 — intervention group
Group type: COMPARATOR
Intervention: Control (standard therapy)
Number of subjects: 406
Study 6105515 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibrate
Number of subjects: 150000
Study 6105515 — intervention group
Group type: COMPARATOR
Intervention: High serum cholesterol (control group)
Number of subjects: 150000
Study 6105515 — intervention group
Group type: COMPARATOR
Intervention: Low cholesterol (control group)
Number of subjects: 150000
Study 31462766 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 222
Study 31462766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 29786570 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin and pioglitazone
Number of subjects: 95
Study 29786570 — intervention group
Group type: COMPARATOR
Intervention: Metformin and sulfonylureas
Number of subjects: 95
Study 27457818 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 104
Study 27457818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 25085855 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane-enriched blood cardioplegia
Number of subjects: 0
Study 23408369 — intervention group
Group type: EXPERIMENTAL
Intervention: Working Memory (WM)
Number of subjects: 60
Study 23408369 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive Control (EC)
Number of subjects: 60
Study 20413040 — intervention group
Group type: COMPARATOR
Intervention: Atenolol-based regimen
Number of subjects: 1006
Study 20413040 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine-based regimen
Number of subjects: 1006
Study 18723286 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine (0.1mg/kg)
Number of subjects: 12
Study 18723286 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine (0.025mg/kg)
Number of subjects: 12
Study 18723286 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 12
Study 18723286 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (after morphine administration)
Number of subjects: 12
Study 18723286 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-painful thermal sensations
Number of subjects: 12
Study 16544087 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2-Hz electrical stimulation
Number of subjects: 16
Study 16544087 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 16
Study 15494904 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin-rifampicin
Number of subjects: 127
Study 15494904 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (flucloxacillin or vancomycin)
Number of subjects: 127
Study 11046207 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (1.0-1.1% end tidal)
Number of subjects: 8
Study 11046207 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (140 microg. kg‐1. min‐1)
Number of subjects: 8
Study 11046207 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 8
Study 9065360 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivermead Motor Assessment (RMA)
Number of subjects: 3
Study 8327367 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amoxicillin administered 1 hr prior to the procedure
Number of subjects: 26
Study 8327367 — intervention group
Group type: COMPARATOR
Intervention: Flavored syrup as placebo
Number of subjects: 26
Study 2423813 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially purified bean-derived amylase inhibitor with 50 g of starch
Number of subjects: 0
Study 2423813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30357819 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization together with Best Medical Therapy (BMT)
Number of subjects: 158
Study 30357819 — intervention group
Group type: COMPARATOR
Intervention: Best Medical Therapy (BMT) alone
Number of subjects: 158
Study 29771014 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 115
Study 29771014 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous immunotherapy (SCIT)
Number of subjects: 115
Study 25007225 — intervention group
Group type: EXPERIMENTAL
Intervention: Group stress management (GSM) (n = 77)
Number of subjects: 304
Study 25007225 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual stress management (ISM) (n = 78)
Number of subjects: 304
Study 23156067 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing medical education/continuing professional development (five residential events + four short distance-learning refresher courses over one year)
Number of subjects: 60
Study 23156067 — intervention group
Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 60
Study 23156067 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing medical education/continuing professional development
Number of subjects: 60
Study 20234346 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol 400 mg
Number of subjects: 425
Study 20234346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 425
Study 18329221 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (400 mg/day, n = 14)
Number of subjects: 49
Study 18329221 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (60 mg/day, n = 13)
Number of subjects: 49
Study 18329221 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (pericyazine, 2.5‐10 mg/day, n = 22)
Number of subjects: 49
Study 15130899 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 662
Study 15130899 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular gold
Number of subjects: 662
Study 15130899 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 662
Study 15130899 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyramid
Number of subjects: 662
Study 12909071 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amiodarone plus oral verapamil (group A+V)
Number of subjects: 363
Study 12909071 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral flecainide plus oral verapamil (group F+V)
Number of subjects: 363
Study 12909071 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil addition to group A and F patients
Number of subjects: 363
Study 12909071 — intervention group
Group type: COMPARATOR
Intervention: Oral amiodarone (group A)
Number of subjects: 363
Study 12909071 — intervention group
Group type: COMPARATOR
Intervention: Oral flecainide (group F)
Number of subjects: 363
Study 11286371 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Resonance Therapy Music (MRT-Music), 3 x 30 minutes per day for 14 days
Number of subjects: 68
Study 11286371 — intervention group
Group type: COMPARATOR
Intervention: Control group (relaxation during the same time period)
Number of subjects: 68
Study 8803961 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine (2 mg b.i.d. for 8 weeks)
Number of subjects: 0
Study 8803961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8803961 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined calcium and lacidipine administrations
Number of subjects: 0
Study 1395455 — intervention group
Group type: EXPERIMENTAL
Intervention: OB + DZ (20 mg + 2 mg) T.I.D.
Number of subjects: 30
Study 1395455 — intervention group
Group type: COMPARATOR
Intervention: OB alone (20 mg)
Number of subjects: 30
Study 3892676 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 36
Study 3892676 — intervention group
Group type: COMPARATOR
Intervention: Trimazosin
Number of subjects: 36
Study 31405091 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-water hand immersion (5 °C for 15 min)
Number of subjects: 10
Study 30344180 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous human albumin solution (HAS) administered to target serum albumin level of ≥35 g/L for up to 14 days or until discharge.
Number of subjects: 866
Study 30344180 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care (control group).
Number of subjects: 866
Study 27633687 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (enoxaparin) prophylaxis
Number of subjects: 50
Study 27633687 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 50
Study 23511280 — intervention group
Group type: EXPERIMENTAL
Intervention: LiDCO group (hemodynamic monitoring through lithium dilution cardiac output)
Number of subjects: 21
Study 23511280 — intervention group
Group type: COMPARATOR
Intervention: Control group (without LiDCO monitoring)
Number of subjects: 21
Study 21161260 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (n = 25)
Number of subjects: 50
Study 21161260 — intervention group
Group type: COMPARATOR
Intervention: No acetazolamide (n = 25)
Number of subjects: 50
Study 19217592 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline (NS)
Number of subjects: 289
Study 19217592 — intervention group
Group type: EXPERIMENTAL
Intervention: NS with 5% dextrose (D5NS)
Number of subjects: 289
Study 19217592 — intervention group
Group type: EXPERIMENTAL
Intervention: NS with 10% dextrose (D10NS)
Number of subjects: 289
Study 19217592 — intervention group
Group type: COMPARATOR
Intervention: Control (Normal saline)
Number of subjects: 289
Study 17119004 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised 6 week, home based exercise and strategy programme
Number of subjects: 142
Study 17119004 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 142
Study 15540292 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal posterior colporrhaphy
Number of subjects: 30
Study 15540292 — intervention group
Group type: COMPARATOR
Intervention: Transanal rectoceleplasty
Number of subjects: 30
Study 11146780 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiotherapy (45 Gy concurrent radiotherapy and fluorouracil 225‐250 mg/m(2) per day for 5 weeks)
Number of subjects: 12
Study 11146780 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiotherapy
Number of subjects: 12
Study 9444509 — intervention group
Group type: EXPERIMENTAL
Intervention: Social worker supervision (group A)
Number of subjects: 600
Study 9444509 — intervention group
Group type: COMPARATOR
Intervention: No social worker supervision (group B)
Number of subjects: 600
Study 8195686 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning strategy instruction
Number of subjects: 33
Study 8195686 — intervention group
Group type: COMPARATOR
Intervention: Traditional instruction
Number of subjects: 33
Study 3207531 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine
Number of subjects: 16
Study 3207531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31841795 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg monthly subcutaneous injection
Number of subjects: 464
Study 31841795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 464
Study 28867355 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (at least 2.5h/wk)
Number of subjects: 286
Study 28867355 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (at least 1.5h/wk)
Number of subjects: 286
Study 28867355 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (at least 150min/week)
Number of subjects: 286
Study 28282325 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival scenario (manikin responded to appropriate resuscitation)
Number of subjects: 42
Study 28282325 — intervention group
Group type: COMPARATOR
Intervention: Death scenario (manikin remained pulseless despite resuscitation)
Number of subjects: 42
Study 28282325 — intervention group
Group type: EXPERIMENTAL
Intervention: Both scenarios (comparison of salivary cortisol levels)
Number of subjects: 42
Study 25543183 — intervention group
Group type: EXPERIMENTAL
Intervention: Prism adaptation (PA) therapy
Number of subjects: 20
Study 25543183 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 23047659 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksite vaccination program
Number of subjects: 13520
Study 20555256 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress-reduction training (8-week mindfulness-training course)
Number of subjects: 18
Study 18338298 — intervention group
Group type: EXPERIMENTAL
Intervention: In-class and on-road education
Number of subjects: 0
Study 18338298 — intervention group
Group type: COMPARATOR
Intervention: Control group (waited for education)
Number of subjects: 0
Study 18338298 — intervention group
Group type: EXPERIMENTAL
Intervention: On-road evaluation after education
Number of subjects: 0
Study 21961489 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference formulation of metformin hydrochloride (1,000 mg)
Number of subjects: 20
Study 21961489 — intervention group
Group type: COMPARATOR
Intervention: Test formulation of metformin hydrochloride (1,000 mg)
Number of subjects: 20
Study 16143129 — intervention group
Group type: EXPERIMENTAL
Intervention: ursodeoxycholic acid, 8‐10 mg/kg body weight daily (n = 42)
Number of subjects: 84
Study 16143129 — intervention group
Group type: COMPARATOR
Intervention: cholestyramine, 8 g daily (n = 42)
Number of subjects: 84
Study 16143129 — intervention group
Group type: EXPERIMENTAL
Intervention: ursodeoxycholic acid
Number of subjects: 84
Study 16143129 — intervention group
Group type: COMPARATOR
Intervention: cholestyramine
Number of subjects: 84
Study 12392588 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg caffeine (C-replete)
Number of subjects: 12
Study 12392588 — intervention group
Group type: COMPARATOR
Intervention: Placebo (C-naïve)
Number of subjects: 12
Study 12392588 — intervention group
Group type: EXPERIMENTAL
Intervention: C-replete
Number of subjects: 12
Study 9475468 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Health Summary (PHS) score
Number of subjects: 2415
Study 9475468 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Health Summary (MHS) score
Number of subjects: 2415
Study 8076228 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron (5 mg.m‐2)
Number of subjects: 60
Study 8076228 — intervention group
Group type: EXPERIMENTAL
Intervention: metoclopramide (0.12 mg.kg‐1)
Number of subjects: 60
Study 8076228 — intervention group
Group type: COMPARATOR
Intervention: placebo (saline solution)
Number of subjects: 60
Study 8076228 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron
Number of subjects: 60
Study 2574554 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg once daily (qd)
Number of subjects: 392
Study 2574554 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg twice daily (bid)
Number of subjects: 392
Study 12717127 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.5 cm bent length in group A
Number of subjects: 379
Study 12717127 — intervention group
Group type: COMPARATOR
Intervention: 8.5 cm bent length in group A
Number of subjects: 379
Study 12717127 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.5 cm bent length in group B
Number of subjects: 379
Study 12717127 — intervention group
Group type: COMPARATOR
Intervention: 8.5 cm bent length in group B
Number of subjects: 379
Study 31272953 — intervention group
Group type: EXPERIMENTAL
Intervention: Binocular game
Number of subjects: 103
Study 31272953 — intervention group
Group type: EXPERIMENTAL
Intervention: Part-time patching
Number of subjects: 103
Study 31272953 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (binocular game + patching)
Number of subjects: 103
Study 31272953 — intervention group
Group type: COMPARATOR
Intervention: Combined group
Number of subjects: 103
Study 31272953 — intervention group
Group type: COMPARATOR
Intervention: Patching
Number of subjects: 103
Study 29091020 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanobone (NB)
Number of subjects: 14
Study 29091020 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-Oss (BO)
Number of subjects: 14
Study 26364667 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MgSO4) for 12 hours after delivery
Number of subjects: 182
Study 26364667 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulfate (MgSO4) for 24 hours after delivery
Number of subjects: 182
Study 23759442 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol delamination (ALD)
Number of subjects: 33
Study 23759442 — intervention group
Group type: COMPARATOR
Intervention: Phototherapeutic keratectomy (PTK)
Number of subjects: 33
Study 22719840 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra‐operative anaesthetic intervention with BiSpectral index and cerebral oxygen saturation monitoring
Number of subjects: 192
Study 22719840 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 192
Study 20626269 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 10101
Study 20626269 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene with antiplatelet agents
Number of subjects: 10101
Study 20626269 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene without antiplatelet agents
Number of subjects: 10101
Study 20626269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10101
Study 18308753 — intervention group
Group type: EXPERIMENTAL
Intervention: Managed Ventricular Pacing (MVP) algorithm
Number of subjects: 600
Study 18308753 — intervention group
Group type: COMPARATOR
Intervention: Conventional pacemaker and implantable cardioverter‐defibrillator programming
Number of subjects: 600
Study 15937619 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximate PPH stapler
Number of subjects: 50
Study 15937619 — intervention group
Group type: COMPARATOR
Intervention: LigaSure hemorrhoidectomy
Number of subjects: 50
Study 12638114 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (preferred limb practice)
Number of subjects: 0
Study 12638114 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (nonpreferred limb practice)
Number of subjects: 0
Study 12638114 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 12638114 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 and Group 2
Number of subjects: 0
Study 10607813 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rhuMAb‐E25 (5.8 microg/kg/nanogram IgE/mL)
Number of subjects: 317
Study 10607813 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rhuMAb‐E25 (2.5 microg/kg/nanogram IgE/mL)
Number of subjects: 317
Study 10607813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 317
Study 10607813 — intervention group
Group type: EXPERIMENTAL
Intervention: Both rhuMAb‐E25 groups
Number of subjects: 317
Study 8535917 — intervention group
Group type: EXPERIMENTAL
Intervention: High feedback
Number of subjects: 207
Study 8535917 — intervention group
Group type: COMPARATOR
Intervention: Low feedback
Number of subjects: 207
Study 1833682 — intervention group
Group type: EXPERIMENTAL
Intervention: Desogestrel (20 micrograms ethinyl estradiol + 150 micrograms desogestrel)
Number of subjects: 34
Study 1833682 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestodene (30 micrograms ethinyl estradiol + 75 micrograms gestodene)
Number of subjects: 34
Study 6109267 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 0
Study 6109267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30733037 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-row repair with 2 standard suture anchors and 2 knotless anchor devices
Number of subjects: 12
Study 30733037 — intervention group
Group type: COMPARATOR
Intervention: Single-row repair with suture anchors only
Number of subjects: 12
Study 30733037 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-row anchor repair
Number of subjects: 12
Study 30733037 — intervention group
Group type: COMPARATOR
Intervention: Single-row repair
Number of subjects: 12
Study 29899691 — intervention group
Group type: EXPERIMENTAL
Intervention: Real ctDCS
Number of subjects: 6
Study 29899691 — intervention group
Group type: COMPARATOR
Intervention: Sham ctDCS
Number of subjects: 6
Study 26964505 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS intervention (90 SMSes over 17 weeks)
Number of subjects: 223
Study 26964505 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 223
Study 25225000 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy mood
Number of subjects: 0
Study 25225000 — intervention group
Group type: EXPERIMENTAL
Intervention: Sad mood
Number of subjects: 0
Study 25225000 — intervention group
Group type: COMPARATOR
Intervention: Mood induction procedure
Number of subjects: 0
Study 23249810 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% cellulose sulfate (CS; 13 subjects)
Number of subjects: 35
Study 23249810 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% nonoxynol-9 (N-9; 12 subjects)
Number of subjects: 35
Study 23249810 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyethylcellulose (HEC)-based 'universal' placebo (10 subjects)
Number of subjects: 35
Study 20145608 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (2 capsules per day)
Number of subjects: 255
Study 20145608 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (1 capsule + 1 placebo capsule per day)
Number of subjects: 255
Study 20145608 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 capsules per day)
Number of subjects: 255
Study 18044193 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 38
Study 18044193 — intervention group
Group type: COMPARATOR
Intervention: Sham exercise
Number of subjects: 38
Study 16136646 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha‐2a and ribavirin
Number of subjects: 1145
Study 16136646 — intervention group
Group type: COMPARATOR
Intervention: Cirrhosis
Number of subjects: 1145
Study 12503476 — intervention group
Group type: COMPARATOR
Intervention: Mechanical compression device (FemoStop)
Number of subjects: 239
Study 12503476 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual compression
Number of subjects: 239
Study 11331696 — intervention group
Group type: EXPERIMENTAL
Intervention: closed-loop FIO(2) control (cFIO(2))
Number of subjects: 14
Study 11331696 — intervention group
Group type: COMPARATOR
Intervention: manual FIO(2) adjustments (mFIO(2))
Number of subjects: 14